NovoThirteen is a medicine that prevents excessive bleeding in patients with an inherited blood clotting disorder called ‘congenital factor XIII A-subunit deficiency’. It is used to prevent bleeding and to treat any episodes of bleeding that occur during preventative treatment. NovoThirteen contains the active substance catridecacog.
Therapeutic Indication
### Therapeutic indication Long-term prophylactic treatment of bleeding in adult and paediatric patients 6 years and above with congenital factor-XIII-A-subunit deficiency.
Therapeutic Area (MeSH)
ATC Code
B02BD11
ATC Item
catridecacog
Pharmacotherapeutic Group
Antihemorrhagics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| catridecacog | N/A | Catridecacog |
EMA Name
NovoThirteen
Medicine Name
NovoThirteen
Aliases
N/ANo risk management plan link.
